Differential
calcitonin gene-related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: potential models for studying CGRP/amylin receptor subtypes.
Calcitonin gene-related peptide in GCF in periodontal health and disease.
Morphine-induced modulation of
calcitonin gene-related peptide levels.
Swindon Zydis Limited, a subsidiary of Catalent (CTLT) to provide Catalent's Zydis ODT fast-dissolving formulation for the development of Biohaven's lead
calcitonin gene-related peptide, or CGRP, receptor antagonist product candidate, rimegepant.
It functions by targeting and inhibiting the
Calcitonin Gene-Related Peptide (CGRP) receptor, which is considered to play a key role in activation of migraine.
Galcanezumab is a once-monthly, subcutaneously injected
calcitonin gene-related peptide (CGRP) antibody under evaluation for the prevention of episodic and chronic migraine and cluster headache.
Calcitonin gene-related peptide expression in sepsis: postulation of microbial infection-specific response elements within the calcitonin I gene promoter.
Galcanezumab is a monoclonal antibody specifically designed to bind to and inhibit the activity of
calcitonin gene-related peptide, which is believed to play a role in migraine and cluster headache.
According to the company, rimegepant is a second-generation, small molecule,
calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine.
If approved, Aimovig is expected to be the first-and-only monoclonal antibody targeting the
calcitonin gene-related peptide (CGRP) receptor, specifically designed for the prevention of migraine.
